Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort.
DMSO
Sepax 2
autologous stem cell transplantation
hematopoietic cells
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
08
05
2021
received:
17
02
2021
accepted:
17
05
2021
pubmed:
2
7
2021
medline:
20
8
2021
entrez:
1
7
2021
Statut:
ppublish
Résumé
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is routinely used in various hematologic malignancies. However, dimethylsulfoxide contained in cryopreserved grafts can cause adverse events (AEs). Forty-three ASCTs were performed with Sepax 2 washed grafts between 7/2016 and 10/2019. The aim of this study was to determine whether washing out dimethyl sulfoxide (DMSO) from transplants using the Sepax 2 (S-100) device is safe and reduces the incidence of DMSO-associated AEs. The washing procedure was automated and that resulted in the satisfactory recovery of total nucleated cells, CD34 We conclude that the washing of cryopreserved transplants using Sepax 2 was feasible with a high recovery of hematopoietic cells, did not influence time to engraftment, and resulted in the satisfactory reduction of AEs and improved tolerance of the procedure.
Sections du résumé
BACKGROUND
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is routinely used in various hematologic malignancies. However, dimethylsulfoxide contained in cryopreserved grafts can cause adverse events (AEs).
STUDY DESIGN AND METHODS
Forty-three ASCTs were performed with Sepax 2 washed grafts between 7/2016 and 10/2019. The aim of this study was to determine whether washing out dimethyl sulfoxide (DMSO) from transplants using the Sepax 2 (S-100) device is safe and reduces the incidence of DMSO-associated AEs.
RESULTS
The washing procedure was automated and that resulted in the satisfactory recovery of total nucleated cells, CD34
CONCLUSION
We conclude that the washing of cryopreserved transplants using Sepax 2 was feasible with a high recovery of hematopoietic cells, did not influence time to engraftment, and resulted in the satisfactory reduction of AEs and improved tolerance of the procedure.
Substances chimiques
Cryoprotective Agents
0
Dimethyl Sulfoxide
YOW8V9698H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2430-2438Subventions
Organisme : European Regional Development Fund
ID : CZ.02.1.01/0.0/0.0/16_019/0000868
Organisme : European Regional Development Fund
ID : SGS03
Organisme : MH CZ - DRO - FNOs/2020
Organisme : SGS03/PrF/2019-2020
Informations de copyright
© 2021 AABB.
Références
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-26. https://doi.org/10.1056/NEJMra052638
Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525-52. https://doi.org/10.1038/s41409-019-0516-2
Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European consortium of stem cell mobilization. Bone Marrow Transpl. 2012;47:1046-50. https://doi.org/10.1038/bmt.2011.216
Kubiak A, Matuszak P, Bembnista E, Kozlowska-Skrzypczak M. Banking of hematopoietic stem cells: influence of storage time on their quality parameters. Transpl Proc. 2016;48:1806-9. https://doi.org/10.1016/j.transproceed.2016.03.011
Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, et al. Handling, processing and disposal of stem cell products in Europe: a survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy. 2018;20:453-60. https://doi.org/10.1016/j.jcyt.2017.12.005
Winter JM, Jacobson P, Bullough B, Christensen AP, Boyer M, Reems J-A. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. Cytotherapy. 2014;16:965-75. https://doi.org/10.1016/j.jcyt.2014.02.005
Windrum P, Morris TCM, Drake MB, Niederwieser D, Ruutu T. EBMT chronic Leukaemia working party complications subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transpl. 2005;36:601-3. https://doi.org/10.1038/sj.bmt.1705100
Shu Z, Heimfeld S, Gao D. Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transpl. 2014;49:469-76. https://doi.org/10.1038/bmt.2013.152
Alessandrino P, Bernasconi P, Caldera D, Colombo A, Bonfichi M, Malcovati L, et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transpl. 1999;23:533-7. https://doi.org/10.1038/sj.bmt.1701609
Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara SI, et al. Adverse events associated with infusion of hematopoietic stem cell products: a prospective and multicenter surveillance study. Transfus Med Rev. 2018;32(3):186-94. https://doi.org/10.1016/j.tmrv.2018.05.005
Zenhäusern R, Tobler A, Leoncini L, Hess OM, Ferrari P. Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol. 2000;79:523-6. https://doi.org/10.1007/s002770000186
Keung YK, Lau S, Elkayam U, Chen SC, Douer D. Cardiac arrhythmia after infusion of cryopreserved stem cells. Bone Marrow Transpl. 1994;14:363-7.
Maral S, Albayrak M, Pala C, Yildiz A, Sahin O, Ozturk HB. Dimethyl sulfoxide-induced tonic-Clonic seizure and cardiac arrest during infusion of autologous peripheral blood stem cells. Cell Tissue Bank. 2018;19:831-2. https://doi.org/10.1007/s10561-018-9718-x
Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy P. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transpl. 2000;25:1299-301. https://doi.org/10.1038/sj.bmt.1702452
Hoyt R, Szer J, Grigg A. Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transpl. 2000;25:1285-7. https://doi.org/10.1038/sj.bmt.1702443
Hequet O, Dumontet C, El Jaafari-Corbin A, Salles G, Espinouse D, Arnaud P, et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transpl. 2002;29:544. https://doi.org/10.1038/sj.bmt.1703383
Bojanic I, Cepulic BG, Mazic S, Batinic D, Nemet D, Labar B. Toxicity related to autologous peripheral blood haematopoietic progenitor cell infusion is associated with number of granulocytes in graft, gender and diagnosis of multiple myeloma. Vox Sang. 2008;95:70-5. https://doi.org/10.1111/j.1423-0410.2008.01060.x
Calmels B, Lemarié C, Esterni B, Malugani C, Charbonnier A, Coso D, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion. 2007;47:1268-75. https://doi.org/10.1111/j.1537-2995.2007.01267.x
Martín-Henao GA, Resano PM, Villegas JMS, Manero PP, Sanchez JM, Bosch MP, et al. Adverse reactions during transfusion of thawed haematopoietic progenitor cells from apheresis are closely related to the number of granulocyte cells in the leukapheresis product. Vox Sang. 2010;99:267-73. https://doi.org/10.1111/j.1423-0410.2010.01341.x
Abrahamsen JF, Bakken AM, Bruserud Ø. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion. 2002;42:1573-80. https://doi.org/10.1046/j.1537-2995.2002.00242.x
Bakken AM, Bruserud O, Abrahamsen JF. No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. J Hematother Stem Cell Res. 2003;12:351-8. https://doi.org/10.1089/152581603322023089
Mitrus I, Smagur A, Giebel S, Gliwinska J, Prokop M, Glowala-Kosinska M, et al. A faster reconstitution of hematopoiesis after autologous transplantation of hematopoietic cells cryopreserved in 7.5% dimethyl sulfoxide if compared to 10% dimethyl sulfoxide containing medium. Cryobiology. 2013;67:327-31. https://doi.org/10.1016/j.cryobiol.2013.09.167
Morris C, de Wreede L, Scholten M, Brand R, Van Biezen A, Sureda A, et al. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion. 2014;54:2514-22. https://doi.org/10.1111/trf.12759
Smagur A, Mitrus I, Giebel S, Sadus-Wojciechowska M, Najda J, Kruzel T, et al. Impact of different dimethyl sulphoxide concentrations on cell recovery, viability and clonogenic potential of cryopreserved peripheral blood hematopoietic stem and progenitor cells. Vox Sang. 2013;104:240-7. https://doi.org/10.1111/j.1423-0410.2012.01657.x
Scerpa MC, Daniele N, Landi F, Caniglia M, Cometa AM, Ciammetti C, et al. Automated washing of human progenitor cells: evaluation of apoptosis and cell necrosis. Transfus Med. 2011;21:402-7. https://doi.org/10.1111/j.1365-3148.2011.01103.x
Sanchez-Salinas A, Cabanas-Perianes V, Blanquer M, Majado MJ, Insausti CL, Monserrat J, et al. An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion. Transfusion. 2012;52:2382-6. https://doi.org/10.1111/j.1537-2995.2012.03585.x
Mfarrej B, Bouchet G, Couquiaud J, Regimbaud L, Binninger S, Mercier M, et al. Pre-clinical assessment of the Lovo device for dimethyl sulfoxide removal and cell concentration in thawed hematopoietic progenitor cell grafts. Cytotherapy. 2017;19:1501-8. https://doi.org/10.1016/j.jcyt.2017.09.001
Abonnenc M, Pesse B, Tissot J-D, Barelli S, Lion N. Automatic washing of thawed haematopoietic progenitor cell grafts: a preclinical evaluation. Vox Sang. 2017;112:367-78. https://doi.org/10.1111/vox.12503
Calmels B, Houzé P, Hengesse J-C, Ducrot T, Malenfant C, Chabannon C. Preclinical evaluation of an automated closed fluid management device: cytomate, for washing out DMSO from hematopoietic stem cell grafts after thawing. Bone Marrow Transpl. 2003;31:823-8. https://doi.org/10.1038/sj.bmt.1703905
Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transpl. 2019;54:1575-85. https://doi.org/10.1038/s41409-019-0465-9
Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A. 1995;92:10119-22. https://doi.org/10.1073/pnas.92.22.10119
Lemarie C, Calmels B, Malenfant C, Arneodo V, Blaise D, Viret F, et al. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate. Transfusion. 2005;45:737-42. https://doi.org/10.1111/j.1537-2995.2005.04126.x